Core Viewpoint - Hansoh Pharmaceutical (03692) has seen a stock price increase of over 4%, currently trading at HKD 42.12, following the announcement of a new indication approval for its innovative drug, Amelot (Ametinib Mesylate Tablets) by the National Medical Products Administration (NMPA) in China [1] Group 1: Drug Approval and Indications - On January 8, Hansoh Pharmaceutical announced that Amelot received a drug registration certificate from NMPA, approving its use in combination with pemetrexed and platinum-based chemotherapy for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations [1] - This marks the fifth approved indication for Amelot, highlighting the drug's expanding therapeutic potential in oncology [1] Group 2: Research Findings - Recent research results published in the prestigious oncology journal, Lancet Oncology, indicate that Amelot significantly improves disease-free survival (DFS) in patients with completely resected stage II-III B EGFR-mutant NSCLC, with a favorable safety profile [1]

Core Viewpoint - Hansoh Pharmaceutical (03692) has seen a stock price increase of over 4%, currently trading at HKD 42.12, following the announcement of a new indication for its innovative drug Amelot (Ametinib Mesylate Tablets) [1] Group 1: Drug Approval and Indications - On January 8, Hansoh Pharmaceutical announced that its innovative drug Amelot received a drug registration certificate from the National Medical Products Administration (NMPA) in China, approving it for use in combination with pemetrexed and platinum-based chemotherapy for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations [1] - This marks the fifth approved indication for Amelot, highlighting the drug's expanding therapeutic applications [1] Group 2: Research Findings - Recent research results published in the prestigious oncology journal Lancet Oncology indicate that Amelot significantly improves disease-free survival (DFS) in patients with completely resected stage II-III B EGFR-mutant NSCLC, demonstrating good safety [1]

Group 1 - The core point of the news is that Hansoh Pharmaceutical announced the approval of a fifth indication for Amelot (Ametinib Mesylate Tablets) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations [1] - The approval is based on the AENEAS2 Phase III clinical study, which demonstrated that Amelot combined with chemotherapy significantly extends progression-free survival (PFS) compared to monotherapy, with a hazard ratio (HR) of 0.47, indicating a 53% reduction in the risk of disease progression or death [1] - The median PFS was extended to 28.9 months, with an objective response rate (ORR) of 93.2%, and no new safety risks were identified in the study, which included only Chinese patients [1] Group 2 - Since its initial approval in March 2020, Amelot has expanded from a single indication to five, with all previous indications included in the national medical insurance catalog, enhancing its clinical position and providing high-level evidence for the treatment of lung cancer in China [2] - The previously approved indications include postoperative adjuvant therapy for EGFR-mutant NSCLC, maintenance therapy after chemoradiotherapy for unresectable locally advanced NSCLC, and first-line and second-line treatments for advanced NSCLC [2]

Core Viewpoint - Hansoh Pharmaceutical (03692) announced that its innovative drug Amelot (Ametinib Mesylate Tablets) has received a drug registration certificate from the National Medical Products Administration (NMPA) in China, approving the addition of a new indication for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. This marks the fifth approved indication for Amelot [1]. Group 1 - Hansoh Pharmaceutical's Amelot has received approval for a new indication in NSCLC treatment [1] - The new indication involves the combination of Amelot with pemetrexed and platinum-based chemotherapy [1] - This approval represents the fifth indication for the drug, highlighting its expanding therapeutic potential [1]

Core Viewpoint - Hansoh Pharmaceutical (03692) has received a drug registration certificate from the National Medical Products Administration (NMPA) for its innovative drug Amelot (Ametinib Mesylate Tablets), approving its fifth indication for use in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [1] Group 1 - The new indication allows Amelot to be used in combination with pemetrexed and platinum-based chemotherapy for patients with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations [1]

Core Viewpoint - The mid-term performance announcement of Hansoh Pharmaceutical highlights the company's clear innovation transformation and internationalization strategy, with significant growth in revenue and profit driven by innovative drugs and collaborative products [2][3]. Financial Performance - In the first half of 2025, Hansoh Pharmaceutical reported revenue of approximately RMB 74.34 billion, a year-on-year increase of about 14.3%, and a profit of approximately RMB 31.35 billion, up by about 15.0% [2]. - Basic earnings per share reached approximately RMB 0.53, reflecting a year-on-year growth of about 14.8% [2]. Innovation and Product Sales - Sales revenue from innovative drugs and collaborative products amounted to approximately RMB 61.45 billion, marking a year-on-year increase of 22.1% and accounting for about 82.7% of total revenue [2][3]. - The company has seen a significant shift from "generic-innovative combination" to "innovation-driven" strategies, indicating a successful transformation in response to policy guidance and market demand [2][3]. Collaborative Agreements - In the first half of 2025, Hansoh received a BD licensing fee of USD 112 million from Merck, and in June 2025, it granted Regeneron exclusive overseas licensing rights for the GLP-1/GIP dual receptor agonist HS-20094, receiving an upfront payment of USD 80 million [2]. - The company is also engaged in multiple collaborations, including a partnership with Lupo Pharmaceutical for the BTK inhibitor LP-168, which aims to expand its pipeline for autoimmune diseases [6][7]. Research and Development Investment - Hansoh's R&D expenditure reached RMB 14.41 billion in the first half of 2025, representing a year-on-year increase of 20.4% and accounting for 19.4% of total revenue [6]. - The company is pursuing a dual-track strategy of "introduction and output," enhancing its product pipeline and reducing risks associated with single R&D projects [6][10]. Market Position and Industry Trends - The 82.7% share of innovative revenue significantly exceeds the industry average of 50%-70% for leading domestic pharmaceutical companies [3]. - The Chinese innovative drug sector has seen over 50 BD outbound transactions by June 30, 2025, with a total disclosed cooperation amount of USD 48.448 billion, marking a historic high [9]. Strategic Evolution - The industry is shifting from "single transactions" to "ecosystem co-construction," with deeper collaboration across the pharmaceutical value chain, including partnerships with biotech firms and research institutions [10]. - The trend indicates a move towards strategic binding and shared interests among partners, enhancing long-term value and reducing risks associated with new product development [10].

Core Viewpoint - The mid-term performance announcement of Hansoh Pharmaceutical highlights the company's clear innovation transformation and internationalization strategy, showcasing significant growth in revenue and profit driven by innovative drugs and collaborative products [1][2]. Financial Performance - In the first half of 2025, Hansoh Pharmaceutical reported revenue of approximately RMB 7.434 billion, a year-on-year increase of about 14.3%, and a profit of approximately RMB 3.135 billion, up 15.0% year-on-year [1]. - Basic earnings per share reached approximately RMB 0.53, reflecting a year-on-year growth of 14.8% [1]. Revenue Composition - Sales revenue from innovative drugs and collaborative products amounted to approximately RMB 6.145 billion, representing a year-on-year increase of 22.1% and accounting for about 82.7% of total revenue [1][2]. - The revenue breakdown for the first half of 2025 includes approximately RMB 4.531 billion from oncology, RMB 735 million from anti-infection, RMB 768 million from central nervous system, and RMB 1.400 billion from metabolic and other diseases, with respective contributions of 60.9%, 9.9%, 10.4%, and 18.8% to total revenue [2]. R&D Investment - R&D expenditure for the first half of 2025 was RMB 1.441 billion, a year-on-year increase of 20.4%, constituting 19.4% of total revenue [3]. Strategic Collaborations - Hansoh has adopted a dual-track approach of "introduction and output" in its innovation strategy, signing various collaboration agreements to enhance its product pipeline and reduce risks associated with single R&D projects [3][4]. - Notable collaborations include a partnership with Merck for a BD licensing fee of USD 112 million and exclusive licensing agreements with Regeneron and other companies for innovative drug development [1][3][5]. Industry Trends - The proportion of innovative drug revenue at 82.7% is significantly higher than the industry average of 50%-70%, indicating a successful strategic shift from "generic-innovative combination" to "innovation-driven" [2][6]. - The Chinese innovative drug sector has seen over 50 BD outbound transactions with a total disclosed cooperation amount of USD 48.448 billion, marking a historic high and reflecting the industry's maturation [6][7]. Future Outlook - The trend towards deeper collaboration within the industry is evident, with companies moving from single transactions to ecosystem co-construction, enhancing R&D efficiency and market value [7]. - The shift from financial investment to strategic binding in partnerships is expected to create long-term value and reduce risks associated with new product introductions [7].

Core Viewpoint - Hansoh Pharmaceutical Group announced the approval of Amelot (Ametinib Mesylate Tablets) for a new indication, expanding its application to treat adult non-small cell lung cancer (NSCLC) patients with specific EGFR mutations [1][2] Group 1: Product Approval and Clinical Research - The new indication is for patients with stage II-III B NSCLC who have previously undergone surgical resection and may or may not receive adjuvant chemotherapy [1] - The approval is based on the ARTS (HS-10296-302) Phase III clinical study, which was presented at the 2025 American Association for Cancer Research (AACR) annual meeting [1] - The ARTS study demonstrated a significant improvement in disease-free survival (DFS) for patients receiving Amelot as adjuvant therapy, with a 2-year DFS rate of 90.2% [1] Group 2: Market Position and Expansion - Amelot, as China's first original third-generation EGFR-TKI, has been expanding its treatment areas since its launch five years ago [2] - The recent approval allows Amelot to cover early to mid-stage NSCLC (II-III stage), providing more treatment options for lung cancer patients in China [2]

Core Viewpoint - The 2025 CSCO Guidelines Conference has introduced the 2025 edition of the CSCO Guidelines for the Diagnosis and Treatment of Primary Non-Small Cell Lung Cancer (NSCLC), highlighting the inclusion of Hansoh Pharmaceutical's Amelot (Ametinib Mesylate Tablets) as the first Chinese original third-generation EGFR-TKI to receive a Class I recommendation for consolidation therapy in EGFR mutation-positive stage III unresectable NSCLC patients after chemoradiotherapy [1][2][3] Group 1 - The new recommendation is based on positive results from the POLESTAR study, a nationwide, multicenter, randomized, double-blind, controlled phase III clinical trial assessing the efficacy and safety of Amelot in consolidation therapy for stage III unresectable NSCLC patients with EGFR mutations after chemoradiotherapy [2] - The mid-term analysis of the POLESTAR study, presented at the 2024 World Lung Cancer Conference, showed a median progression-free survival (mPFS) of 30.4 months for the Amelot group, compared to 3.8 months for the placebo group, indicating an 8-fold improvement and an 85% reduction in the risk of disease progression or death [2] - The POLESTAR study exclusively included Chinese patients, demonstrating the significant efficacy of original EGFR-TKIs for domestic patients and providing high clinical relevance for China [2] Group 2 - NSCLC accounts for approximately 85% of all lung cancer cases in China, with nearly one-third being locally advanced (stage III) NSCLC, highlighting the urgent need for more precise and effective treatment options [2] - The rapid development of third-generation EGFR-TKIs represents a significant advancement in targeted therapy, offering more treatment choices to improve the diagnosis and treatment levels of stage III unresectable NSCLC and enhance patient prognosis [2] - The inclusion of Amelot as a Class I recommendation for consolidation therapy in this context confirms its application potential and is expected to guide the development of precision diagnosis and treatment for NSCLC in China, ultimately benefiting patients [3]